SIGLEC-15 is indicated as a new immune checkpoint for thyroid cancer [35] since it acts as a putative oncogene, activating the STAT1/STAT3 signaling pathway to promote thyroid cancer cell growth, leading to an increase in immunosuppression [35]. Here, STAT3 is linked to thyroid gland carcinoma.